- Home
- NWFL vs DSGN Comparison
NWFL vs DSGN Comparison
Compare NWFL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWFL
- DSGN
- Stock Information
- Founded
- NWFL 1870
- DSGN 2017
- Country
- NWFL United States
- DSGN United States
- Employees
- NWFL N/A
- DSGN N/A
- Industry
- NWFL Major Banks
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- NWFL Finance
- DSGN Health Care
- Exchange
- NWFL Nasdaq
- DSGN Nasdaq
- Market Cap
- NWFL 249.5M
- DSGN 264.4M
- IPO Year
- NWFL 1998
- DSGN 2021
- Fundamental
- Price
- NWFL $29.83
- DSGN $5.57
- Analyst Decision
- NWFL
- DSGN Hold
- Analyst Count
- NWFL 0
- DSGN 3
- Target Price
- NWFL N/A
- DSGN $7.00
- AVG Volume (30 Days)
- NWFL 9.1K
- DSGN 142.1K
- Earning Date
- NWFL 10-28-2024
- DSGN 11-07-2024
- Dividend Yield
- NWFL 4.11%
- DSGN N/A
- EPS Growth
- NWFL N/A
- DSGN N/A
- EPS
- NWFL 1.59
- DSGN N/A
- Revenue
- NWFL $62,305,000.00
- DSGN N/A
- Revenue This Year
- NWFL N/A
- DSGN N/A
- Revenue Next Year
- NWFL N/A
- DSGN N/A
- P/E Ratio
- NWFL $18.39
- DSGN N/A
- Revenue Growth
- NWFL N/A
- DSGN N/A
- 52 Week Low
- NWFL $23.50
- DSGN $2.13
- 52 Week High
- NWFL $34.50
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- NWFL 50.30
- DSGN 47.80
- Support Level
- NWFL $29.23
- DSGN $5.32
- Resistance Level
- NWFL $31.40
- DSGN $7.77
- Average True Range (ATR)
- NWFL 1.06
- DSGN 0.58
- MACD
- NWFL -0.25
- DSGN -0.09
- Stochastic Oscillator
- NWFL 22.68
- DSGN 19.12
About NWFL Norwood Financial Corp.
Norwood Financial Corp is a U.S.-based bank holding company. It offers various personal and business credit services, trust and investment products, and real estate settlement services to consumers, businesses, nonprofit organizations, and municipalities in each of the communities that the bank serves. The bank also manages automated teller machines at its branch location. It serves the Pennsylvanian counties of Wayne, Pike, Monroe, and Lackawanna, as well as Susquehanna County.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.